Northeast Financial Consultants’s Lineage Cell Therapeutics LCTX Stock Holding History

Northeast Financial Consultants’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-523,756	Closed	-$491K	–	323
2020 Q3	$491K	Hold	523,756	–	–	0.04%	175
2020 Q2	$456K	Hold	523,756	–	–	0.04%	178
2020 Q1	$434K	Hold	523,756	–	–	0.05%	172
2019 Q4	$466K	Sell	523,756 -170,100	-25%	-$142K	0.04%	189
2019 Q3	$680K	Buy	693,856 +142,000	+26%	+$147K	0.07%	159
2019 Q2	$607K	Buy	551,856 +142,000	+35%	+$164K	0.06%	168
2019 Q1	$537K	Buy	+409,856	New	+$510K	0.06%	173
2014 Q3	–	Sell	-156,425	Closed	-$385K	–	142
2014 Q2	$385K	Hold	156,425	–	–	0.22%	81
2014 Q1	$415K	Hold	156,425	–	–	0.24%	78
2013 Q4	$454K	Buy	+156,425	New	+$473K	0.3%	62

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $15.5B AUM 38.81% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Northeast Financial Consultants's LCTX Position: Q4 2020 in Review

Northeast Financial Consultants sold out of Lineage Cell Therapeutics (LCTX) in Q4 2020, closing a stake of 523,756 shares — an estimated $491K sold.

Northeast Financial Consultants first reported a position in LCTX in Q4 2013 and held it in 10 quarters. The position peaked at $680K in Q3 2019. 89 funds tracked by Wall St. Rank hold LCTX as of Q4 2020.

Northeast Financial Consultants reported no remaining Lineage Cell Therapeutics position as of Q4 2020 after selling out during the quarter.
Northeast Financial Consultants sold 523,756 Lineage Cell Therapeutics shares in Q4 2020, an estimated $491K.
Northeast Financial Consultants first reported a position in Lineage Cell Therapeutics in Q4 2013 and held it in 10 quarters.
Northeast Financial Consultants's Lineage Cell Therapeutics position peaked at $680K in Q3 2019.
89 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2020.

Based on Northeast Financial Consultants's 13F filing for Q4 2020, filed 12 Feb 2021.